vs
Side-by-side financial comparison of Bally's Corp (BALY) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $746.2M, roughly 2.0× Bally's Corp). Organon & Co. runs the higher net margin — 10.0% vs -47.3%, a 57.3% gap on every dollar of revenue. On growth, Bally's Corp posted the faster year-over-year revenue change (28.6% vs -3.5%). Over the past eight quarters, Bally's Corp's revenue compounded faster (9.8% CAGR vs -4.7%).
Bally's Corporation is an American gambling, betting, and interactive entertainment company headquartered in Providence, Rhode Island. In the US it operates 19 casinos across 11 states, a horse track in Colorado, a golf course in New York, and online sports betting operations in 14 states. In Australia, it operates two properties across two states through its Star Entertainment Group subsidiary.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
BALY vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $746.2M | $1.5B |
| Net Profit | $-353.2M | $146.0M |
| Gross Margin | — | 53.6% |
| Operating Margin | -36.8% | — |
| Net Margin | -47.3% | 10.0% |
| Revenue YoY | 28.6% | -3.5% |
| Net Profit YoY | -311.8% | 67.8% |
| EPS (diluted) | $-5.84 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $746.2M | $1.5B | ||
| Q3 25 | $663.7M | $1.6B | ||
| Q2 25 | $657.5M | $1.6B | ||
| Q1 25 | $368.7M | $1.5B | ||
| Q4 24 | $580.4M | $1.6B | ||
| Q3 24 | $630.0M | $1.6B | ||
| Q2 24 | $621.7M | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $-353.2M | $-205.0M | ||
| Q3 25 | $-102.9M | $160.0M | ||
| Q2 25 | $-228.4M | $145.0M | ||
| Q1 25 | $34.5M | $87.0M | ||
| Q4 24 | $-85.8M | $109.0M | ||
| Q3 24 | $-247.9M | $359.0M | ||
| Q2 24 | $-60.2M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | -36.8% | -9.8% | ||
| Q3 25 | 0.1% | 15.2% | ||
| Q2 25 | -0.4% | 14.4% | ||
| Q1 25 | -0.5% | 6.7% | ||
| Q4 24 | -5.6% | 8.1% | ||
| Q3 24 | -25.0% | 13.1% | ||
| Q2 24 | 0.9% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | -47.3% | -13.6% | ||
| Q3 25 | -15.5% | 10.0% | ||
| Q2 25 | -34.7% | 9.1% | ||
| Q1 25 | 9.4% | 5.8% | ||
| Q4 24 | -14.8% | 6.8% | ||
| Q3 24 | -39.3% | 22.7% | ||
| Q2 24 | -9.7% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $-5.84 | $-0.78 | ||
| Q3 25 | $-1.70 | $0.61 | ||
| Q2 25 | $-3.76 | $0.56 | ||
| Q1 25 | $0.57 | $0.33 | ||
| Q4 24 | $-1.76 | $0.42 | ||
| Q3 24 | $-5.10 | $1.38 | ||
| Q2 24 | $-1.24 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $798.4M | — |
| Total DebtLower is stronger | $4.5B | — |
| Stockholders' EquityBook value | $994.7M | — |
| Total Assets | $11.2B | — |
| Debt / EquityLower = less leverage | 4.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $798.4M | $574.0M | ||
| Q3 25 | $160.7M | $672.0M | ||
| Q2 25 | $174.6M | $599.0M | ||
| Q1 25 | $209.7M | $547.0M | ||
| Q4 24 | $171.2M | $675.0M | ||
| Q3 24 | $191.0M | $763.0M | ||
| Q2 24 | $154.7M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $4.5B | $8.6B | ||
| Q3 25 | $3.7B | $8.8B | ||
| Q2 25 | $3.6B | $8.9B | ||
| Q1 25 | $3.5B | $9.0B | ||
| Q4 24 | $3.3B | $8.9B | ||
| Q3 24 | $3.7B | $8.7B | ||
| Q2 24 | $3.7B | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $994.7M | $752.0M | ||
| Q3 25 | $521.5M | $906.0M | ||
| Q2 25 | $630.1M | $733.0M | ||
| Q1 25 | $796.5M | $542.0M | ||
| Q4 24 | $30.9M | $472.0M | ||
| Q3 24 | $233.4M | $493.0M | ||
| Q2 24 | $393.1M | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $11.2B | $12.9B | ||
| Q3 25 | $7.6B | $13.6B | ||
| Q2 25 | $7.8B | $13.5B | ||
| Q1 25 | $7.5B | $13.2B | ||
| Q4 24 | $5.9B | $13.1B | ||
| Q3 24 | $6.4B | $12.8B | ||
| Q2 24 | $6.6B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 4.52× | 11.49× | ||
| Q3 25 | 7.17× | 9.74× | ||
| Q2 25 | 5.68× | 12.14× | ||
| Q1 25 | 4.33× | 16.52× | ||
| Q4 24 | 107.40× | 18.81× | ||
| Q3 24 | 15.73× | 17.75× | ||
| Q2 24 | 9.34× | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BALY
| Casinos Resorts | $366.2M | 49% |
| Non Casino | $172.7M | 23% |
| Food And Beverage | $74.6M | 10% |
| Hotel | $69.9M | 9% |
| North America Interactive | $62.3M | 8% |
| Loyalty Programs | $6.7M | 1% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
